在质母细胞瘤中基于temozolomide的治疗:6个月与12个月相比
Morena Fasano1, Mario Pirozzi1, Vincenzo De Falco2
1Medical Oncology Unit, Department of Precision Medicine, University of Campania Luigi Vanvitelli, I-80131 Naples, Italy.
Oncology letters
|July 15, 2024
概括
对质母细胞瘤的扩展辅助性泰莫佐洛米德 (TMZ) 治疗显示出更好的生存率. 十二个周期的TMZ显着使患者受益,特别是那些没有甲基化MGMT的患者,与六个周期相比.
科学领域:
- 神经瘤学神经瘤学
- 临床癌症研究 临床癌症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 斯塔普治疗方案是质母细胞瘤的标准,但预后不好.
- 替代的temozolomide方案,包括延长辅助治疗,产生相互矛盾的结果.
研究的目的:
- 在新诊断的质母细胞瘤患者中,比较辅助性temozolomide6周期和12周期的疗效.
- 研究甲基瓜因-DNA-甲基转移酶 (MGMT) 促进剂甲基化状态对治疗结果的影响.
主要方法:
- 在2012年至2022年期间接受治疗的87名质母细胞瘤患者的回顾性生存数据分析.
- 患者接受了6个周期 (6C组,n=45) 或12个周期 (12C组,n=42) 的泰莫索洛米德.
- 评估了异酸脱酶突变和MGMT促进剂甲基化状态.
主要成果:
- 与6C组相比,12C组的整体存活率 (OS) (22.8个月与17.5个月) 和无进展存活率 (PFS) (15.3个月与9个月) 显著改善.
- 对于12C组,仅在MGMT未甲基化瘤患者中观察到显著的OS益处.
- 危险比率表明12个周期的生存优势很大 (OS的HR=0.47,PFS的HR=0.39).
结论:
- 延长辅助剂泰莫索洛米德 (12 个周期) 似乎比常规的六个周期对质母细胞瘤更有效.
- 促进MGMT甲基化状态是对延长的泰莫佐洛米德治疗反应的关键预测生物标志物.
- 需要进一步的前性研究来证实泰莫索洛米德在质母细胞瘤治疗中的最佳持续时间.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...